CN1339319A - 一种治疗艾滋病的药物及其制备方法 - Google Patents
一种治疗艾滋病的药物及其制备方法 Download PDFInfo
- Publication number
- CN1339319A CN1339319A CN00123486A CN00123486A CN1339319A CN 1339319 A CN1339319 A CN 1339319A CN 00123486 A CN00123486 A CN 00123486A CN 00123486 A CN00123486 A CN 00123486A CN 1339319 A CN1339319 A CN 1339319A
- Authority
- CN
- China
- Prior art keywords
- epitope
- medicine
- aids
- immune deficiency
- deficiency syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000030507 AIDS Diseases 0.000 title claims abstract description 52
- 239000003814 drug Substances 0.000 title claims abstract description 35
- 238000000034 method Methods 0.000 title claims description 12
- 229940079593 drug Drugs 0.000 title description 5
- 229920001184 polypeptide Polymers 0.000 claims abstract description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 18
- 230000003472 neutralizing effect Effects 0.000 claims abstract description 17
- 230000008878 coupling Effects 0.000 claims abstract description 13
- 238000010168 coupling process Methods 0.000 claims abstract description 13
- 238000005859 coupling reaction Methods 0.000 claims abstract description 13
- 239000002671 adjuvant Substances 0.000 claims abstract description 11
- 239000000427 antigen Substances 0.000 claims abstract description 5
- 102000036639 antigens Human genes 0.000 claims abstract description 5
- 108091007433 antigens Proteins 0.000 claims abstract description 5
- 102000014914 Carrier Proteins Human genes 0.000 claims abstract description 4
- 108010078791 Carrier Proteins Proteins 0.000 claims abstract description 4
- 241001465754 Metazoa Species 0.000 claims abstract description 3
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 29
- 208000011580 syndromic disease Diseases 0.000 claims description 24
- 230000036039 immunity Effects 0.000 claims description 10
- 210000004408 hybridoma Anatomy 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000007910 cell fusion Effects 0.000 claims description 4
- 238000011091 antibody purification Methods 0.000 claims description 2
- 241000700605 Viruses Species 0.000 abstract description 5
- 230000007812 deficiency Effects 0.000 abstract description 3
- 230000003053 immunization Effects 0.000 abstract description 2
- 108010052285 Membrane Proteins Proteins 0.000 abstract 2
- 102000018697 Membrane Proteins Human genes 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000013329 compounding Methods 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229940124321 AIDS medicine Drugs 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- LLXVXPPXELIDGQ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(2,5-dioxopyrrol-1-yl)benzoate Chemical compound C=1C=CC(N2C(C=CC2=O)=O)=CC=1C(=O)ON1C(=O)CCC1=O LLXVXPPXELIDGQ-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000000680 avirulence Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000001814 protein method Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN00123486A CN1339319A (zh) | 2000-08-18 | 2000-08-18 | 一种治疗艾滋病的药物及其制备方法 |
| AU2002212074A AU2002212074A1 (en) | 2000-08-18 | 2001-07-20 | A pharmaceutical composition for treating acids and its preparation |
| PCT/CN2001/001191 WO2002026259A1 (fr) | 2000-08-18 | 2001-07-20 | Medicament pour le traitement du sida et son procede de preparation |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN00123486A CN1339319A (zh) | 2000-08-18 | 2000-08-18 | 一种治疗艾滋病的药物及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1339319A true CN1339319A (zh) | 2002-03-13 |
Family
ID=4589906
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN00123486A Pending CN1339319A (zh) | 2000-08-18 | 2000-08-18 | 一种治疗艾滋病的药物及其制备方法 |
Country Status (3)
| Country | Link |
|---|---|
| CN (1) | CN1339319A (fr) |
| AU (1) | AU2002212074A1 (fr) |
| WO (1) | WO2002026259A1 (fr) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103459410A (zh) * | 2011-02-25 | 2013-12-18 | 埃斯特韦实验室有限公司 | HIV gp-120变体的快速选择方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5266478A (en) * | 1987-05-29 | 1993-11-30 | Tanox Biosystems, Inc. | Antibodies which target a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120 |
| JPH0292298A (ja) * | 1988-09-30 | 1990-04-03 | Olympus Optical Co Ltd | Ｈｉｖ構成蛋白に対するモノクローナル抗体 |
| CA2094611C (fr) * | 1991-08-22 | 2000-07-25 | Tsuneya Ohno | Produits immunotherapeutiques contre l'infection a vih |
| US5618922A (en) * | 1994-07-25 | 1997-04-08 | Nissin Shokuhin Kabushiki Kaisha | NM03 antibody materials and methods |
| MX9708008A (es) * | 1995-04-19 | 1998-03-31 | Polymun Scient Immunbio Forsch | Anticuerpos monoclonales contra vih-1 y vacunas hechas de los mismos. |
| NZ334941A (en) * | 1996-10-10 | 2000-11-24 | Probe Internat | Methods for treating infections using proteins which induce an immune response in one animal species but not in another |
-
2000
- 2000-08-18 CN CN00123486A patent/CN1339319A/zh active Pending
-
2001
- 2001-07-20 WO PCT/CN2001/001191 patent/WO2002026259A1/fr active Application Filing
- 2001-07-20 AU AU2002212074A patent/AU2002212074A1/en not_active Abandoned
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103459410A (zh) * | 2011-02-25 | 2013-12-18 | 埃斯特韦实验室有限公司 | HIV gp-120变体的快速选择方法 |
| CN103459410B (zh) * | 2011-02-25 | 2016-05-25 | 埃斯特韦实验室有限公司 | HIV gp-120变体的快速选择方法 |
| US9605030B2 (en) | 2011-02-25 | 2017-03-28 | Laboratorios Del Dr. Esteve, S.A. | Rapid selection method for HIV gp-120 variants |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002026259A1 (fr) | 2002-04-04 |
| AU2002212074A1 (en) | 2002-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1651266B1 (fr) | Administration de fragments d'anticorps f(ab')2 anti-tnf-alpha | |
| AU2011286486B2 (en) | Drug and method for the prophylaxis of HIV infection and for the prophylaxis and treatment of diseases caused by or associated with HIV, including aids | |
| EP0822941A1 (fr) | Anticorps monoclonaux contre vih 1 et vaccins en decoulant | |
| EA029436B1 (ru) | Комбинированная фармацевтическая композиция для лечения рассеянного склероза и инфекционных заболеваний, сопровождающихся нейротоксическими нарушениями, и способы лечения указанных заболеваний | |
| CN103189072B (zh) | 免疫刺激方法 | |
| JPH09509164A (ja) | 免疫グロブリンａを用いた炎症を予防及び治療するための組成物並びに方法 | |
| US6132721A (en) | Non-Toxic immunogens derived from a retroviral regulatory protein, antibodies, preparation method therefor, and pharmaceutical compositions containing same | |
| RU2517084C2 (ru) | Способ и средство для ингибирования продукции или усиления элиминации белка р24 | |
| MXPA06009805A (es) | Peptidos de interleucina 1 beta y factor de necrosis tumoral alfa y metodo de tratamiento utilizando los mismos. | |
| CN1172717C (zh) | 一种治疗艾滋病的药物及其制备方法 | |
| WO2001060156A1 (fr) | Compositions renforçant les anticorps neutralisants et les immunomodulateurs | |
| CN1438245A (zh) | 传染性病原体相关蛋黄抗体的制备及应用 | |
| US6200575B1 (en) | Non-toxic immunogens derived from a retroviral regulatory protein antibodies preparation process and pharmaceutical compositions comprising them | |
| CN101214372A (zh) | 一种体内诱导出针对TNF-α分子的自身抗体的蛋白疫苗的构建方法 | |
| JPH04506666A (ja) | ワクチンアジュバントとしてのｌｆａ―３ | |
| RU2006129097A (ru) | Новые тат-комплексы и включающие их вакцины | |
| EP0719281B1 (fr) | Constructions de peptides a branches multiples destines a etre utilises contre le vih | |
| CN1339319A (zh) | 一种治疗艾滋病的药物及其制备方法 | |
| CN1339320A (zh) | 一种艾滋病疫苗及其制备方法与应用 | |
| EP2106802A1 (fr) | Peptides modifiés en tant que vaccins synthétiques dans une maladie associée à l'amyloïde | |
| CA2481325C (fr) | Composition anti-vih, comprenant un polyanion et un agent agissant sur gp120 de acon equivalent au cd4 | |
| RU2217166C2 (ru) | Гуманизированные антитела, которые распознают веротоксин ii, и продуцирующая их линия клеток | |
| EP2138513A1 (fr) | Compositions pharmaceutiques d'anticorps pour les maladies causées par les virus | |
| JPH0236129A (ja) | ワクチン効果増強剤 | |
| RU2203071C2 (ru) | Применение белков в качестве антиретровирусных агентов |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |